<small>Primary cutaneous lymphomas (PCLs) are the second most common
group of extranodal non-Hodgkin lymphomas (NHL) with an estimated annual
incidence of 1/100.000. Interferons (IFNs) are used in mono or
combination therapy for cutaneous lymphomas especially for cutaneous
T-cell lymphomas (CTCL) for years. IFN-α is the most widely-used type
for cutaneous lymphomas. IFN-α has been shown to be a highly active
agent in CTCL with response rates ranging from 40% to 80%. In this
review, the current information about PCLs and IFNs treatment is
summarized.</small
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.